Figure 5 | Scientific Reports

Figure 5

From: The synergy of the XPO1 inhibitors combined with the BET inhibitor INCB057643 in high-grade B-cell lymphoma via downregulation of MYC expression

Figure 5

Downregulation of MYC expression contributes to the synergy of INCB057643 and selinexor. (A,B) qRT–PCR and Western blot analyses revealed that INCB057643 and selinexor interacted with each other to downregulate MYC mRNA (A) and protein expression (B) in both OCI-LY19 and TMD8 cells. (C) Western blot analysis of MYC expression, the potential molecular mechanism of the therapeutic cooperation of INCB057643 and selinexor in TP53-mutated TMD8 cell death. (D) Western blot analysis of the indicated proteins in TP53 wild-type OCI-LY19 cells treated with INCB057643 and selinexor alone or in combination. ***P < 0.001.

Back to article page